NCT06562998

Pentoxifylline Role Against Chemotherapy-induced Neuropathy

Pentoxifylline Prophylactic Role Against Paclitaxel Chemotherapy-induced Neuropathy

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: Beni-Suef University · Academic / Other
• Sex: Female
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side effect of neurotoxic cancer treatment. Estimated to occur in up to 80% of paclitaxel-treated patients with breast cancer, neuropathy symptoms can interfere with function, increasing the risk of falls and reducing quality of life. To date, there are no approved medications for the prevention and/or treatment of CIPN. The objective of the present study is to investigate the beneficial effects of pentoxifylline (PTX) against CIPN in breast cancer patients.

Conditions

• Chemotherapy-induced Peripheral Neuropathy

Interventions

Type	Name	Description
DRUG	Pentoxifylline	Pentoxifylline 400mg twice daily plus paclitaxel based regimens for 12weeks.

Timeline

• Start date: 2022-07-01
• Primary completion: 2024-04-01
• Completion: 2024-08-01
• First posted: 2024-08-20
• Last updated: 2024-08-20

Locations

1 site across 1 country: Egypt